The number of product-liability lawsuits accusing GLP-1 drug makers of causing a rare, sometimes-permanent vision-loss condition has grown steadily since late September 2026, with new cases filed in multiple states against Novo Nordisk and Eli Lilly. The suits center on non-arteritic anterior ischemic optic neuropathy, or NAION, a condition caused by interrupted blood flow to the optic nerve.

What the Lawsuits Allege

Plaintiffs in recent filings, including cases reported out of Massachusetts and Maryland in September and October 2026, say they developed sudden, irreversible vision loss in one eye within weeks of starting semaglutide (Ozempic or Wegovy) or tirzepatide (Mounjaro or Zepbound), and allege the companies knew or should have known about the risk and failed to adequately warn patients and prescribers. The complaints largely follow a familiar product-liability structure: failure to warn, design defect, and, in some filings, misrepresentation claims. As of this writing, the cases have been filed individually rather than consolidated into a single coordinated proceeding, though attorneys quoted in recent coverage say they expect the volume of filings to keep rising.

What the Underlying Science Actually Shows

The litigation traces back to a 2024 observational study, published in JAMA Ophthalmology, that found patients prescribed semaglutide at a single academic eye center had a higher relative risk of developing NAION over three years compared with patients prescribed other diabetes or weight-loss medications. Subsequent research, including larger retrospective database studies, has produced mixed results: some found an elevated relative risk, particularly among patients with type 2 diabetes, while others found no statistically significant association once underlying cardiovascular and diabetes-related risk factors were accounted for. NAION itself is rare in the general population, and even the studies reporting an elevated relative risk describe the absolute increase in individual risk as small. This site's dedicated explainer on GLP-1 medications and the NAION research goes through that evidence base in more detail.

Where Things Stand With Regulators

Neither the FDA nor European regulators have required a boxed warning for NAION on GLP-1 drug labels as of this writing, though the FDA has acknowledged the signal and tracks it through its routine adverse-event surveillance systems. Novo Nordisk's and Eli Lilly's prescribing information for their respective GLP-1 products disclose reports of vision changes and, in some cases, specifically reference NAION or optic neuropathy among post-marketing reports, language that is distinct from a formal warning tied to a confirmed causal finding.

Why This Is Hard to Prove in Court

NAION has other well-established risk factors independent of any medication, including diabetes, high blood pressure, sleep apnea, and a specific optic-disc anatomy sometimes called a "disc at risk." Because the large majority of GLP-1 patients also have one or more of those underlying risk factors, establishing that the drug itself, rather than the condition it was prescribed to treat, caused a given patient's vision loss is a genuine scientific and legal challenge. That same difficulty is part of why the research findings have been inconsistent rather than uniformly pointing in one direction.

What It Means If You're Taking a GLP-1 Medication

NAION remains rare, and the current evidence does not establish that GLP-1 drugs reliably cause it. Sudden vision loss or vision changes in one eye are a medical emergency regardless of the cause, and anyone who experiences them should seek immediate medical attention rather than waiting to see if symptoms resolve. Patients with questions about their own eye-health risk factors, including diabetes-related eye disease, should talk to their prescribing doctor or an ophthalmologist rather than drawing conclusions from lawsuit filings, which reflect legal allegations rather than settled scientific findings.

The Bottom Line

The litigation is a real and growing legal development, but it is running ahead of a scientific picture that is still unsettled. How courts handle the causation question, and whether regulators eventually require updated warning language, will likely do more to clarify the actual risk than the number of lawsuits filed.